Upadacitinib exhibits Efficacy and High Retention in Atopic Dermatitis Treatment, reveals study
Real-world data from Australian patients show that upadacitinib demonstrates strong efficacy in treating atopic dermatitis, with a high treatment retention rate and a 90.5% survival probability at four weeks. This research, carried out by a group under Nadine Abu-Ghazaleh at the Royal Melbourne Hospital, indicates the high rates of persistence of this biologic drug in real-world practice, affirming its practical efficacy and long-term performance. The research is particularly relevant with the hitherto scarce Australian evidence regarding upadacitinib in atopic dermatitis, although it has been listed on the Pharmaceutical Benefits Scheme (PBS). The study was published in the Australasian Journal of Dermatology.
The study team conducted a retrospective analysis based on data obtained from the Royal Melbourne Hospital's BioGrid Database and electronic medical records. Participants were adults aged 18 years and above with moderate-to-severe chronic atopic dermatitis who had at least one upadacitinib prescription via PBS or a Compassionate Supply program. Patient demographics, comorbidities, EASI scores, Dermatology Life Quality Index (DLQI) scores, and previous treatments were collected.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.